Gastric adenomas in familial adenomatous polyposis are common, but subtle, and have a benign course by Saowanee Ngamruengphong et al.
Ngamruengphong et al. Hereditary Cancer in Clinical Practice 2014, 12:4
http://www.hccpjournal.com/content/12/1/4RESEARCH Open AccessGastric adenomas in familial adenomatous
polyposis are common, but subtle, and have a
benign course
Saowanee Ngamruengphong1, Lisa A Boardman2, Russell I Heigh3, Murli Krishna4, Maegan E Roberts5
and Douglas L Riegert-Johnson1,5*Abstract
Background: Patients with familial adenomatous polyposis (FAP) are known to have an increased risk for gastric
adenomas. The clinical features of gastric adenomas in FAP have not been well characterized, and there is a lack of
standardized approaches to the management of these lesions.
Aims: To study the endoscopic appearance, risk factors, clinical course, and response to therapy of gastric
adenomas in patients with FAP.
Methods: We retrospectively reviewed the records of 97 patients with FAP who underwent
esophagogastroduodenoscopy (EGD) at Mayo Clinic (Florida, Rochester and Arizona) between 2004 and 2013.
Results: Nine patients (9%) had biopsy-proven gastric adenomas. Adenomas were located in the antrum (five patients),
in the body and fundus in the setting of background fundic gland polyps (FGP) (three patients), and in the body not
associated with FGP (one patient). Adenoma size was 3–40 mm and the number of adenomas per patient ranged from
one to 20. Adenomas in the antrum were flat and subtle, whereas those in the gastric body or fundus were polypoid
and difficult to differentiate from the cystic FGPs seen in patients with FAP. The performing endoscopists reported
difficulty with identifying adenomas, and six patients had at least one EGD within the previous three years where
gastric adenomas were not reported. Adenomas were classified as tubular in eight patients and tubulovillous in one
patient. High grade dysplasia was noted in one patient. After a median follow-up of 63 months (interquartile range:
20–149 months), no patient in our entire cohort (with or without gastric adenomas) developed gastric cancer. The
patients in whom gastric adenoma developed, compared to those without gastric adenoma, were more likely to be
younger [36 ± 12 vs. 48 ± 15 years, p = 0.02], have concomitant chronic gastritis [22% vs. 0%, p = 0.008], and have
desmoid tumors [5 (56%) vs. 19 (22%), p = 0.04].
Conclusions: Gastric adenomas are not uncommon in patients with FAP and are often difficult to identify
endoscopically. Endoscopists should have a high degree of suspicion for gastric adenomas in these patients and a low
threshold to biopsy. Given the benign clinical course, recommended initial management is conservative with
endoscopic therapy and periodic surveillance.
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Familial adenomatous polyposis (FAP) is an inherited
autosomal-dominant disease primarily characterized by
the development of colorectal adenomas and carcinomas.
Patients with FAP may also secondarily develop duodenal,
gastric, and thyroid neoplasia, as well as desmoid tumors
[1]. Recently, with the widespread application of endo-
scopic and genetic screening with prophylactic colon sur-
gery [2], the incidence of colorectal cancer has declined in
FAP patients. As a result, the long-term survival of FAP
patients is now expected to be determined by the deve-
lopment of extracolonic neoplasia [3]. While duodenal
and thyroid neoplasia and desmoid tumors have been well
studied in FAP patients, detailed clinical data on gastric
adenomas is lacking.
The prevalence of gastric adenomas in FAP was about
10% in a series from the United States and ranged from
36-50% in three studies from Asia [4-6]. It is unclear if gas-
tric adenomas in FAP patients confer an increased risk for
carcinogenesis through the adenoma-carcinoma sequence
or another pathway. Risk factors for the development of
gastric adenomas in the setting of FAP, their typical endo-
scopic appearance, and the appropriate treatment are not
clearly defined. We performed a retrospective review of
FAP patients who had undergone esophagogastroduode-
noscopy (EGD) in our institution to optimize the diagnos-
tic and clinical management of these lesions.
Methods
We identified 97 FAP and attenuated FAP patients who
had had an EGD between January 2004 and December
2012 at Mayo Clinic (Arizona, Florida and Minnesota).
Patients were identified by retrospective review of several
clinical databases. All patients had a diagnosis of FAP or
attenuated FAP established by accepted criteria utilizing
personal and family history, clinical examination, histo-
pathological assessment, and APC gene mutation testing.
The study was approved by the Mayo Clinic Institutional
Review Board.
For each patient, data was collected including age, gender,
family history of gastric cancer, the presence of cystic fundic
gland polyps (FGP), gastric adenomas, and duodenal aden-
omas with severity staged using the modified Spigelman
classification [7], the presence of desmoid tumors, smoking
history, and use of nonsteroidal anti-inflammatory drugs
(NSAID) and/or proton pump inhibitors (PPI). In patients
with gastric adenomas, we retrieved data on endoscopic
and histological characteristics, type of directed therapy,
procedure-related complications, development of cancer,
and length of follow-up.
Statistical analyses
The Pearson chi-square test or Fisher exact test was used
to assess the univariate associations between a categoricalvariable and the presence of gastric adenoma. The student
t test was used for age. A two-tailed p-value was used in
all the analyses. A p-value < 0.05 was considered statis-
tically significant. All data were analyzed using SPSS
Statistics software (version 16; IBM Corporation, USA).
Results
Nine of 97 patients with FAP (9.2%) had biopsy-proven
gastric adenomas. Mean age at the time of diagnosis with a
gastric adenoma was 36 years (range 18–52 years). The
median follow-up for the entire cohort was 63 months
(interquartile range: 20–149 months). High-grade dysplasia
(HGD) was found in one patient (Patient 7) at their initial
diagnosis of gastric adenoma (Table 1).
Of the nine patients with gastric adenomas, four had ad-
enomas located in the gastric antrum, three had adenoma-
tous polyps associated with FGP, one had adenomas in the
gastric body without underlying FGP, and one patient had
adenomas in the gastric antrum and the gastric cardia.
Gastric adenomas ranged in size from 3-40 mm and the
number of adenomas ranged from one to 20 per patient.
Adenomas in the antrum were flat, sessile, and subtle with
a villiform red appearance, whereas those in gastric body
or fundus were polypoid, lobular with pale yellow surface,
and difficult to differentiate from the benign FGP seen in
patients with FAP (Figures 1 and 2). A majority of perfor-
ming endoscopists reported that the adenomas were diffi-
cult to identify. Six patients had at least one EGD within
the previous three years with no reported endoscopic fin-
dings suggesting adenomas. Histology was tubular in eight
patients and tubulovillous in one patient. None of the nine
patients with gastric adenoma had Helicobacter pylori.
Various endoscopic techniques were performed for the
diagnosis and treatment of gastric adenomas (Table 1).
Seven of nine patients had follow-up EGD (all except
Patients 3 and 4). Four of seven patients (Patients 1, 6,
8, 9) had no residual adenoma. These patients had rela-
tively small adenomas (3–6 mm) and all were treated
with cold biopsy forceps. Three patients (Patients 2, 5, 7)
with numerous (13 to more than 20) and larger size of
adenomas (8–40 mm) had residual adenoma at follow-up
EGD. Patient 7, with multiple antral gastric adenomas
containing HGD, underwent three endoscopic resections
with hot snare and the most recent follow-up biopsies
still showed HGD. This patient died from complications
of a desmoid tumor. All other patients were alive at last
follow up. After a median follow-up of 12 months (inter-
quartile range 10–44 months) after initial gastric aden-
oma diagnosis, none of our patients had a progression to
more advanced neoplasia from baseline pathology, in-
cluding development of gastric cancer. None of the pa-
tients experienced procedure-related complications.
The FAP patients in whom gastric adenomas developed,
as compared to those without gastric adenomas, were
Table 1 Clinical characteristics of familial adenomatous polyposis patients with gastric adenomas










1 52 F Flat Antrum 1 NA Tubular CBF × 1 9 No residual adenoma
at last EGD
2 24 M Sessile Body in the
background of FGP
Multiple 40 Tubulovillous Endoscopic
mucosal resection × 1
3 Residual adenoma
3 51 F Sessile Antrum 3 10 Tubular CBF × 1 11 Pending repeat EGD




Multiple 5 Tubular CBF × 1 12 Pending repeat EGD
5 39 M Flat and sessile Antrum 20 8 Tubular CBF × 2 19 Residual adenoma
6 51 F Sessile Body Multiple 3 Tubular CBF × 4 109 No residual adenoma at the
last EGD
7 38 F Sessile Antrum >13 15 Tubular with
HGD
Hot snare × 3 11 HGD was present at the last EGD.
Death due to desmoid tumor.
8 32 F NA Body in the
background of FGP
Multiple 4 Tubular CBF × 2 65 No residual adenoma at last EGD
9 24 M Sessile Antrum, cardia 2 6 Tubular CBF × 1 23 No residual adenoma at last EGD




















Figure 1 Patient 5. (A) Several small sessile tubular adenomas in the gastric antrum of a 39-year-old male patient with familial adenomatous polyposis
(arrows). The adenomas have a flat-topped, villiform appearance. (B) A photomicrograph of a gastric adenoma from this patient demonstrates a tubular
adenoma with low grade dysplasia, characterized by nuclear hyperchromasia and glandular crowding (H&E stain, magnification × 100).
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p = 0.02], have concomitant chronic gastritis [2 (22%) vs.
0 (0%), p = 0.008], and have desmoid tumors [5 (56%) vs.
19 (22%), p = 0.04]. We found no significant difference in
gender, family history of gastric cancer, smoking, the
presence of FGP or duodenal adenoma, the proportion of
patients with modified Spigelman’s grade III or IV duo-
denal polyposis, and NSAID and proton pump inhibitor
use between patients with and without gastric adenomas
(Table 2).
Discussion
Gastric adenomas are of concern because of their sus-
pected potential to transform into gastric cancer. The risk
of gastric cancer in FAP was reported to be increased in
Korean patients, with a standardized incidence ratio of 6.9
(95% confidence interval 1.4-20.1) [8]. This increased risk
may be attributable to the high background risk of gastric
cancer in the Korean population. Only a few cases of gas-
tric cancer have been reported in Western FAP patients
[9-11]. In this series, with a median of five years of follow-
up, no patient with or without a gastric adenoma wasFigure 2 Patient 2. (A) A pedunculated adenoma, about 4 cm in diameter w
The lesion has a lobular, pale yellow surface and arises from a background of cy
same polyp showing an adenoma with low grade dysplasia associated with andiagnosed with gastric cancer. In 1992, another American
FAP center also reported that FAP patients were not at an
increased risk for gastric cancer compared to the general
population [12]. A review of all of the evidence, shows no
indication that Western FAP patients with or without gas-
tric adenomas are at higher risk than the general popu-
lation for gastric cancer. For definitive confirmation, a
population based study of a large number of FAP patients
would be needed.
In the current study, gastric adenomas were detected
in about 9% of patients with FAP, similar to another
study of an American population [4]. This is the first re-
port of detailed endoscopic data, risk factor analysis, and
follow-up data of gastric adenomas in a Western FAP
population. Our study has shown that adenomas tend to
be multiple and commonly occur in the gastric antrum,
but can arise in other areas of stomach. Small gastric
adenomas are likely to be successfully managed by endo-
scopic treatment. While endoscopic therapy for large
and/or multiple lesions seems to be associated with risk
of residual adenoma, none of these patients had a pro-
gression to advanced neoplasia from baseline pathology.as found in a 24-year-old male patient with familial adenomatous polyposis.
stic fundic gland polyps in the gastric body. (B) A photomicrograph of the
underlying cystic fundic gland polyp (H&E stain, magnification × 100).
Table 2 Characteristics of familial adenomatous polyposis
patients with and without gastric adenomas (n = 97)
Variables Gastric
adenoma





Age: range +/− SD; yr 36 +/− 12 48 +/− 15 0.02
Male (%) 4 (44%) 37 (42%) 1.00
Race 0.05
White 6 (67%) 81 (92%)
Non-white 3 (33%) 7 (8%)
Family history of gastric
cancer
0 (0%) 3 (3%) 0.85
Fundic gland polyps 7 (78%) 68 (77%) 1.00
Chronic gastritis 2 (22%) 0 (0%) 0.01
Any duodenal adenoma 7 (78%) 67 (76%) 1.00
Modified Spigelman’s
grade III or IV duodenal
polyposis
4 (44%) 24 (27%) 0.27
Desmoid tumor 5 (56%) 19 (22%) 0.04
NSAID or COX2 inhibitor use 4 (44%) 32 (36%) 0.85
Proton pump inhibitor use 4 (44%) 25 (28%) 0.58
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some potential for progression.
The tendency to develop multiple gastric adenomas
in FAP patients in our study was similar to a report of
Japanese FAP patients [5,13]. Gastric adenomas had one
of three different presentations: flat or sessile adenomas in
the gastric antrum (most common); “de novo” adenoma-
tous polyps in the gastric body/fundus; and adenomatous
changes arising from FGP. The latter two forms were diffi-
cult to separate in the patients who had numerous FGP.
Three of nine patients in our study had adenomas in the
gastric body/fundus that arose in a background of nume-
rous (carpet-like) FGP. It is possible that these adenomas
arose from benign FGP. In one Italian study, adenomatous
or dysplastic changes within FGP have been reported in
up to 44% of FAP patients [14]. Similarly, a study in
American FAP patients found that dysplasia was detected
in 41% of patients with FGP [4].
We noted that six of nine patients with gastric aden-
omas had at least one EGD within the previous three years
where gastric adenomas were not reported. Since these
adenomatous lesions can be subtle and difficult to differ-
entiate from a carpet of FGP, in some cases adenomas
most likely had been overlooked during previous endosco-
pies. In studies of non-FAP patients, the gastric adenoma/
cancer miss rate by EGD was 11-19% [15,16]. The majo-
rity of missed lesions were due to endoscopist oversight
[17]. In this study of FAP patients, the miss rate appears
to be even higher.
The optimal management for gastric adenomas in
Western FAP patients is unclear due to a paucity of dataregarding prognosis and outcomes of therapy. Iida, et al.
[5] described the natural history of gastric adenomas in
Japanese patients with FAP. They concluded that gastric
adenomas rarely changed over a long periods of time.
One of 13 patients with gastric adenomas developed gas-
tric cancer. This patient had one gastric adenoma that
did not change in size and morphology during four years
of follow-up, but malignant foci was confirmed by endo-
scopic biopsy. In our series, one patient had a tubular
adenoma with HGD, but none had carcinoma. After
endoscopic treatment and close follow-up EGD, pro-
gression to more advanced neoplasia from baseline pa-
thology was not seen in any patients. Given the absence
of malignancy and the response to endoscopic therapy
described in our study, we propose endoscopic manage-
ment with careful periodic surveillance examinations as
the preferred treatment for gastric adenomas in FAP
patients. Surgery should be reserved for patients with
adenomas having advanced histologic features who fail
endoscopic management.
APC mutation data was only available for three patients
with gastric adenomas, which is not enough to make any
comment on a possible genotype/phenotype relationship.
However, there is a well described genotype/phenotype
relationship in FAP for 3′ APC mutations and desmoids
tumors [18]. By extension, a possible relationship between
3′ mutations and gastric adenoma has been suggested, as
we have noted, there is a significantly higher prevalence of
desmoid tumors in FAP patients with gastric adenomas
than those without gastric adenomas. Spigelman et al. [19]
reported a high incidence of gastric adenomas in patients
with severe duodenal polyposis. In their study, five of six
patients with gastric adenomas had stage III or IV duo-
denal disease. In our study, we found no association bet-
ween the presence of gastric adenomas and advanced
duodenal polyposis. Although chronic gastritis was asso-
ciated with gastric adenomas, H. pylori infection was not
found in any of these patients. Review of the records of
patients with gastric adenomas also did not identify any
indication of autoimmune gastritis such as vitamin B12
deficiency or hypothyroidism. Although H. pylori was not
found in the gastric biopsies of patients with chronic gas-
tritis, it is possible that these patients might have had pre-
vious H. pylori infection which had been eradicated.
This was a retrospective study and is limited by the
lack of systemic and consistent patient evaluations. As a
result, we may have underestimated the true prevalence
of gastric adenomas; however, it should be noted that
the prevalence of gastric adenomas in our study is simi-
lar to the previous Western experience [4]. Additionally,
the number of patients with gastric adenomas in our
study is relatively small; and therefore, the study may be
underpowered to reveal true differences in clinical risk
factors and outcomes.
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Gastric adenomas are common in patients with FAP and
can be difficult to identify endoscopically. Endoscopists
should have a high degree of suspicion for gastric aden-
omas in these patients and a low threshold for biopsy.
Given the benign course described and that malignant
transformation is rare in Western FAP patients, conser-
vative management with endoscopic therapy and surveil-
lance is recommended.
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